DE69838979D1 - Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren - Google Patents
Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumorenInfo
- Publication number
- DE69838979D1 DE69838979D1 DE69838979T DE69838979T DE69838979D1 DE 69838979 D1 DE69838979 D1 DE 69838979D1 DE 69838979 T DE69838979 T DE 69838979T DE 69838979 T DE69838979 T DE 69838979T DE 69838979 D1 DE69838979 D1 DE 69838979D1
- Authority
- DE
- Germany
- Prior art keywords
- tumors
- recombinant antibodies
- carrying cells
- immunoconjugates
- immunoconjugates targeted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4143797P | 1997-03-20 | 1997-03-20 | |
| US41437P | 1997-03-20 | ||
| PCT/US1998/005453 WO1998041641A1 (en) | 1997-03-20 | 1998-03-19 | Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69838979D1 true DE69838979D1 (de) | 2008-02-21 |
| DE69838979T2 DE69838979T2 (de) | 2008-12-24 |
Family
ID=21916511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69838979T Expired - Lifetime DE69838979T2 (de) | 1997-03-20 | 1998-03-19 | Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7541034B1 (de) |
| EP (1) | EP0970227B1 (de) |
| JP (3) | JP2002501488A (de) |
| AT (1) | ATE383430T1 (de) |
| AU (1) | AU740904B2 (de) |
| CA (1) | CA2284665C (de) |
| DE (1) | DE69838979T2 (de) |
| ES (1) | ES2300122T3 (de) |
| WO (1) | WO1998041641A1 (de) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU740904B2 (en) | 1997-03-20 | 2001-11-15 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors |
| US6183744B1 (en) * | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| JP3835827B2 (ja) | 1997-05-02 | 2006-10-18 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ リプレゼンティッド バイ ザ セクレタリーオブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 悪性細胞に対する、ｏｎｃタンパク質を含む、免疫毒素 |
| US7696325B2 (en) | 1999-03-10 | 2010-04-13 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide inducing apoptosis |
| CA2411102A1 (en) | 2000-06-20 | 2001-12-27 | Idec Pharmaceutical Corporation | Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination |
| ATE391174T1 (de) | 2000-10-20 | 2008-04-15 | Chugai Pharmaceutical Co Ltd | Modifizierter tpo-agonisten antikörper |
| US20020159996A1 (en) | 2001-01-31 | 2002-10-31 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| DE60236450D1 (de) * | 2001-09-26 | 2010-07-01 | Us Health | Mutierte anti-cd22-antikörper mit erhöhter affinität zu cd22-exprimierenden leukämiezellen |
| GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
| TWI379693B (en) | 2002-05-02 | 2012-12-21 | Wyeth Corp | Calicheamicin derivative-carrier conjugates |
| JP2004279086A (ja) | 2003-03-13 | 2004-10-07 | Konica Minolta Holdings Inc | 放射線画像変換パネル及び放射線画像変換パネルの製造方法 |
| EP1689783B1 (de) | 2003-11-25 | 2010-05-19 | The Government Of The United States, As Represented by The Secretary Of Health And Human Services | Mutierte anti-cd22-antikörper und immunkonjugate |
| ES2592271T3 (es) | 2005-03-31 | 2016-11-29 | Chugai Seiyaku Kabushiki Kaisha | Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos |
| EP1870458B1 (de) | 2005-03-31 | 2018-05-09 | Chugai Seiyaku Kabushiki Kaisha | sc(Fv)2-STRUKTURISOMERE |
| JP2008539731A (ja) | 2005-05-02 | 2008-11-20 | コールド スプリング ハーバー ラボラトリー | 癌の診断及び治療のための組成物及び方法 |
| CN101262885B (zh) | 2005-06-10 | 2015-04-01 | 中外制药株式会社 | 含有sc(Fv)2的药物组合物 |
| KR101367544B1 (ko) | 2005-06-10 | 2014-02-26 | 추가이 세이야쿠 가부시키가이샤 | 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용 |
| GEP20135917B (en) | 2006-03-17 | 2013-09-10 | Biogen Idec Inc | Stabilized polypeptide compositions |
| WO2007114325A1 (ja) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | 二重特異性抗体を精製するための抗体改変方法 |
| WO2009124109A1 (en) | 2008-04-04 | 2009-10-08 | The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services | Human monoclonal antibodies specific for cd22 |
| US9238878B2 (en) | 2009-02-17 | 2016-01-19 | Redwood Bioscience, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
| WO2011031441A1 (en) | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
| ES2544805T3 (es) | 2009-09-11 | 2015-09-04 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Exotoxina A de Pseudomonas mejorada con inmunogenicidad reducida |
| PL3434346T3 (pl) | 2010-07-30 | 2021-04-06 | Medimmune, Llc | Oczyszczone aktywne polipeptydy lub immunokoniugaty |
| CN103415621A (zh) | 2011-01-14 | 2013-11-27 | 雷德伍德生物科技股份有限公司 | 醛标记免疫球蛋白多肽及其使用方法 |
| EP3138581B1 (de) | 2011-03-17 | 2019-01-02 | The University of Birmingham | Umgelenkte immuntherapie |
| ES2635416T3 (es) | 2011-06-09 | 2017-10-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Exotoxina A de pseudomonas con epítopos de linfocitos T y/o linfocitos B menos inmunogénicos |
| US8932586B2 (en) | 2011-09-06 | 2015-01-13 | Intrexon Corporation | Modified forms of Pseudomonas exotoxin A |
| EP3301110A1 (de) | 2011-09-16 | 2018-04-04 | The USA, as represented by The Secretary, Department of Health and Human Services | Pseudomonas exotoxin a mit weniger immunogenen b-zellepitopen |
| CN109485730A (zh) * | 2011-10-20 | 2019-03-19 | 美国卫生和人力服务部 | 抗cd22嵌合抗原受体 |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| RU2015105588A (ru) | 2012-07-19 | 2016-09-10 | Редвуд Байосайнс, Инк. | Антитело, специфическое к cd22, и способы его применения |
| WO2014100443A2 (en) * | 2012-12-20 | 2014-06-26 | Medimmune, Llc | Methods of producing immunoconjugates |
| US9890369B2 (en) | 2013-06-20 | 2018-02-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor |
| SG11201602261VA (en) | 2013-09-27 | 2016-04-28 | Chugai Pharmaceutical Co Ltd | Method for producing polypeptide heteromultimer |
| EP3038641B1 (de) | 2013-10-06 | 2019-04-17 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Modifiziertes pseudomonas-exotoxin a |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| JP2018508481A (ja) | 2015-02-02 | 2018-03-29 | ザ ユニバーシティ オブ バーミンガム | 複数のｔ細胞エピトープを有する標的化部分ペプチドエピトープ複合体 |
| WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
| US20180258143A1 (en) | 2015-05-30 | 2018-09-13 | Molecular Templates, Inc. | De-Immunized, Shiga Toxin A Subunit Scaffolds and Cell-Targeting Molecules Comprising the Same |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| PT3377103T (pt) | 2015-11-19 | 2021-05-26 | Revitope Ltd | Complementação de fragmento de anticorpo funcional para um sistema de dois componentes para exterminação redirecionada de células indesejadas |
| CA3004288A1 (en) | 2015-12-28 | 2017-07-06 | Nobuyuki Tanaka | Method for promoting efficiency of purification of fc region-containing polypeptide |
| CN109071634A (zh) | 2016-04-26 | 2018-12-21 | R.P.谢勒技术有限责任公司 | 抗体偶联物及其制备和使用方法 |
| WO2019055955A1 (en) | 2017-09-18 | 2019-03-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | IMMUNOTOXINS WITH ALBUMIN BINDING DOMAIN |
| US20230212286A1 (en) | 2020-06-01 | 2023-07-06 | Innobation Bio Co., Ltd. | Antibodies specific for cd22 and uses thereof |
| MX2023000339A (es) | 2020-07-10 | 2023-02-09 | Hoffmann La Roche | Anticuerpos que se unen a celulas cancerosas y dirigen radionucleotidos a dichas celulas. |
| JP2023544457A (ja) * | 2020-09-29 | 2023-10-23 | クンミン シノウェイ ナチュラル ファーマシューティカルズ カンパニー リミテッド | ヒト化抗ｃｄ２２組換え免疫毒素およびその用途 |
| KR102393776B1 (ko) | 2020-12-30 | 2022-05-04 | (주)이노베이션바이오 | Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체 |
| WO2022146891A2 (en) | 2020-12-31 | 2022-07-07 | Sana Biotechnology, Inc. | Methods and compositions for modulating car-t activity |
| TW202242121A (zh) | 2021-01-11 | 2022-11-01 | 美商薩那生物科技公司 | 靶向cd8之病毒載體之用途 |
| CA3204291A1 (en) | 2021-01-13 | 2022-07-21 | F. Hoffmann-La Roche Ag | Combination therapy |
| EP4314049A1 (de) | 2021-03-25 | 2024-02-07 | Dynamicure Biotechnology LLC | Anti-igfbp7-konstrukte und verwendungen davon |
| CA3219352A1 (en) | 2021-05-19 | 2022-11-24 | Sonja SCHREPFER | Hypoimmunogenic rhd negative primary t cells |
| IL308097A (en) | 2021-05-27 | 2023-12-01 | Sana Biotechnology Inc | Hypoimmunogenic cells that include transgenic HLA-E or HLA-G |
| WO2023287827A2 (en) | 2021-07-14 | 2023-01-19 | Sana Biotechnology, Inc. | Altered expression of y chromosome-linked antigens in hypoimmunogenic cells |
| WO2023015217A1 (en) | 2021-08-04 | 2023-02-09 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
| WO2023019227A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
| AU2022325955A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
| AU2022326565A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
| CA3227108A1 (en) | 2021-08-11 | 2023-02-16 | Xiaomeng HU | Genetically modified primary cells for allogeneic cell therapy |
| WO2023019203A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Inducible systems for altering gene expression in hypoimmunogenic cells |
| WO2023069790A1 (en) | 2021-10-22 | 2023-04-27 | Sana Biotechnology, Inc. | Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods |
| TW202342498A (zh) | 2021-12-17 | 2023-11-01 | 美商薩那生物科技公司 | 經修飾副黏液病毒科融合醣蛋白 |
| TW202342757A (zh) | 2021-12-17 | 2023-11-01 | 美商薩那生物科技公司 | 經修飾副黏液病毒科附著醣蛋白 |
| WO2023122337A1 (en) | 2021-12-23 | 2023-06-29 | Sana Biotechnology, Inc. | Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| WO2023158836A1 (en) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56145222A (en) * | 1980-04-28 | 1981-11-11 | Toshiyuki Hamaoka | Improved antibody and its preparation |
| US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US5476659A (en) | 1982-11-09 | 1995-12-19 | The Scripps Research Institute | Cancerous B cell treatment using substituted nucleoside derivatives |
| GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5258498A (en) * | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5506126A (en) | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
| US5045451A (en) | 1988-10-26 | 1991-09-03 | Board Of Regents | Methods for screening antibodies for use as immunotoxins |
| US5165923A (en) | 1989-11-20 | 1992-11-24 | Imperial Cancer Research Technology | Methods and compositions for the treatment of hodgkin's disease |
| US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| US5591629A (en) * | 1994-04-29 | 1997-01-07 | Mayo Foundation For Medical Education & Research | Monoclonal antibodies which promote central nervous system remyelination |
| AU740904B2 (en) * | 1997-03-20 | 2001-11-15 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors |
-
1998
- 1998-03-19 AU AU67646/98A patent/AU740904B2/en not_active Expired
- 1998-03-19 EP EP98912977A patent/EP0970227B1/de not_active Expired - Lifetime
- 1998-03-19 WO PCT/US1998/005453 patent/WO1998041641A1/en active IP Right Grant
- 1998-03-19 DE DE69838979T patent/DE69838979T2/de not_active Expired - Lifetime
- 1998-03-19 CA CA2284665A patent/CA2284665C/en not_active Expired - Lifetime
- 1998-03-19 ES ES98912977T patent/ES2300122T3/es not_active Expired - Lifetime
- 1998-03-19 AT AT98912977T patent/ATE383430T1/de active
- 1998-03-19 JP JP54081298A patent/JP2002501488A/ja not_active Withdrawn
- 1998-03-19 US US09/381,497 patent/US7541034B1/en not_active Expired - Fee Related
-
2008
- 2008-03-18 JP JP2008070484A patent/JP2008208131A/ja active Pending
-
2009
- 2009-04-30 US US12/433,737 patent/US9592304B2/en not_active Expired - Fee Related
-
2010
- 2010-03-31 JP JP2010084519A patent/JP2010200752A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US7541034B1 (en) | 2009-06-02 |
| EP0970227B1 (de) | 2008-01-09 |
| DE69838979T2 (de) | 2008-12-24 |
| ES2300122T3 (es) | 2008-06-01 |
| ATE383430T1 (de) | 2008-01-15 |
| US20090305411A1 (en) | 2009-12-10 |
| CA2284665A1 (en) | 1998-09-24 |
| US9592304B2 (en) | 2017-03-14 |
| JP2008208131A (ja) | 2008-09-11 |
| CA2284665C (en) | 2010-08-17 |
| AU740904B2 (en) | 2001-11-15 |
| AU6764698A (en) | 1998-10-12 |
| JP2010200752A (ja) | 2010-09-16 |
| EP0970227A1 (de) | 2000-01-12 |
| JP2002501488A (ja) | 2002-01-15 |
| WO1998041641A1 (en) | 1998-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69838979D1 (de) | Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren | |
| TR200301846T2 (tr) | Cripto bloke edici Antikorlar ve bu antikorların kullanımları. | |
| DE69910216D1 (de) | Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung | |
| ATE365562T1 (de) | Zielgerichtete kombinations-immuntherapie für krebs | |
| ATE412432T1 (de) | Internalisierende erbb2 antikörper | |
| CY1119291T1 (el) | Πολυσθενη αντισωματα και χρησεις για αυτα | |
| ATE368054T1 (de) | Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität | |
| CY1111863T1 (el) | Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων | |
| DE69637781D1 (de) | Für den il-13 rezeptor spezifische chimäre proteine und ihre verwendungen | |
| BR9914116A (pt) | Composições e métodos para imunoterapia especìfica de wt1 | |
| IL195338A (en) | An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use | |
| BR0209862A (pt) | Imunoconjugados de anticorpos de cd44 citotóxicos | |
| ATE476495T1 (de) | Bazillus thuringiensis und dessen insektizide proteine | |
| DE69839444D1 (de) | Smad 6 und dessen anwendungen | |
| WO2000018439A3 (de) | Verwendung von neoangiogenese-markern für diagnose und therapie von tumoren | |
| ATE527358T1 (de) | Ribosomen inaktivierendes protein vom typ-1 | |
| BR0014860A (pt) | Métodos para a produção de uma molécula alvo em um animal transgênico e purificação da molécula alvo | |
| ATE331728T1 (de) | Proteinmarkierung mit radioaktivem phospor und gezielte radiotherapie | |
| NZ504291A (en) | Compositions and methods for targeted delivery of factors | |
| DE69700983D1 (de) | Ligandgerichtete enzyme-prodrug therapie | |
| ATE414100T1 (de) | Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen | |
| ID25478A (id) | Agonis 5-ht1f | |
| ATE249243T1 (de) | Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat | |
| DK1011329T3 (da) | 7-Methylthiooxomethyl- og 7-methylthiodioxomethyl-paclitaxeler | |
| TR200103405T2 (tr) | İkiişlevli antikorlar ve bunların tümör-önleyici amilleri hedeflemede kullanımı. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |